PMID- 32971497
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 191
DP  - 2020 Nov 30
TI  - The role of gut microbiota (GM) and GM-related metabolites in diabetes and 
      obesity. A review of analytical methods used to measure GM-related metabolites in 
      fecal samples with a focus on metabolites' derivatization step.
PG  - 113617
LID - S0731-7085(20)31503-X [pii]
LID - 10.1016/j.jpba.2020.113617 [doi]
AB  - Disruption of gut microbiota (GM) composition is increasingly related to the 
      pathogenesis of various metabolic diseases. Additionally, GM is responsible for 
      the production and transformation of metabolites involved in the development of 
      metabolic disorders, such as obesity and type 2 diabetes mellitus (T2DM). The 
      current state of knowledge regarding the composition of GM and GM-related 
      metabolites in relation to the progress and development of obesity and T2DM is 
      presented in this review. To understand the relationships between GM-related 
      metabolites and the development of metabolic disorders, their accurate 
      qualitative and quantitative measurement in biological samples is needed. Feces 
      represent a valuable biological matrix which composition may reflect the health 
      status of the lower gastrointestinal tract and the whole organism. Mass 
      spectrometry (MS), mainly in combination with gas chromatography (GC) or liquid 
      chromatography (LC), is commonly used to measure fecal metabolites. However, 
      profiling metabolites in such a complex matrix as feces is challenging from both 
      analytical chemistry and biochemistry standpoints. Chemical derivatization is one 
      of the most effective methods used to overcome these problems. In this review, we 
      provide a comprehensive summary of the derivatization methods of GM-related 
      metabolites prior to GC-MS or LC-MS analysis, which have been published in the 
      last five years (2015-2020). Additionally, analytical methods used for the 
      analysis of GM-related metabolites without the derivatization step are also 
      presented.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Mojsak, Patrycja
AU  - Mojsak P
AD  - Metabolomics Laboratory, Clinical Research Centre, Medical University of 
      Bialystok, Bialystok, Poland.
FAU - Rey-Stolle, Fernanda
AU  - Rey-Stolle F
AD  - Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and 
      Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, 
      Urbanizacion Monteprincipe, 28660 Boadilla del Monte, Madrid, Spain.
FAU - Parfieniuk, Ewa
AU  - Parfieniuk E
AD  - Metabolomics Laboratory, Clinical Research Centre, Medical University of 
      Bialystok, Bialystok, Poland.
FAU - Kretowski, Adam
AU  - Kretowski A
AD  - Metabolomics Laboratory, Clinical Research Centre, Medical University of 
      Bialystok, Bialystok, Poland; Department of Endocrinology, Diabetology and 
      Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
FAU - Ciborowski, Michal
AU  - Ciborowski M
AD  - Metabolomics Laboratory, Clinical Research Centre, Medical University of 
      Bialystok, Bialystok, Poland. Electronic address: michal.ciborowski@umb.edu.pl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200915
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
SB  - IM
MH  - *Diabetes Mellitus, Type 2
MH  - Feces
MH  - Gas Chromatography-Mass Spectrometry
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Obesity
OTO - NOTNLM
OT  - Derivatization
OT  - Diabetes
OT  - GC-MS
OT  - LC-MS
OT  - Microbiota
OT  - Obesity
COIS- Declaration of Competing Interest The authors report no declarations of interest.
EDAT- 2020/09/25 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/24 20:19
PHST- 2020/05/15 00:00 [received]
PHST- 2020/08/31 00:00 [revised]
PHST- 2020/09/02 00:00 [accepted]
PHST- 2020/09/25 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/24 20:19 [entrez]
AID - S0731-7085(20)31503-X [pii]
AID - 10.1016/j.jpba.2020.113617 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2020 Nov 30;191:113617. doi: 10.1016/j.jpba.2020.113617. 
      Epub 2020 Sep 15.